BRIEF-Puma Biotechnology Licensing Partner Canbridge Pharmaceuticals Receives Registration Approval In Hong Kong For Nerlynx (Neratinib) For Extended Adjuvant Treatment Of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer

Nov 5 (Reuters) - Puma Biotechnology Inc:

* PUMA BIOTECHNOLOGY LICENSING PARTNER CANBRIDGE PHARMACEUTICALS RECEIVES REGISTRATION APPROVAL IN HONG KONG FOR NERLYNX® (NERATINIB) FOR EXTENDED ADJUVANT TREATMENT OF EARLY STAGE HORMONE RECEPTOR POSITIVE HER2-POSITIVE BREAST CANCER

* PUMA BIOTECHNOLOGY - CANBRIDGE PHARMACEUTICALS INC., HAS RECEIVED REGISTRATION APPROVAL FROM DEPARTMENT OF HEALTH IN HONG KONG TO MARKET NERLYNX Source text for Eikon: Further company coverage: